Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • CorMedix's Other Working Capital Changes fell 29752.12% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 4519.87%. This contributed to the annual value of $2.4 million for FY2024, which is 29921.61% up from last year.
  • As of Q3 2025, CorMedix's Other Working Capital Changes stood at -$1.1 million, which was down 29752.12% from -$461299.0 recorded in Q2 2025.
  • CorMedix's 5-year Other Working Capital Changes high stood at $2.3 million for Q1 2025, and its period low was -$1.1 million during Q3 2025.
  • For the 5-year period, CorMedix's Other Working Capital Changes averaged around $183981.1, with its median value being $8249.5 (2021).
  • As far as peak fluctuations go, CorMedix's Other Working Capital Changes skyrocketed by 155881.58% in 2021, and later tumbled by 245175.0% in 2022.
  • CorMedix's Other Working Capital Changes (Quarter) stood at -$515918.0 in 2021, then surged by 116.42% to $84697.0 in 2022, then surged by 395.39% to $419578.0 in 2023, then soared by 30.48% to $547473.0 in 2024, then plummeted by 302.47% to -$1.1 million in 2025.
  • Its Other Working Capital Changes stands at -$1.1 million for Q3 2025, versus -$461299.0 for Q2 2025 and $2.3 million for Q1 2025.